KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Income from Continuing Operations (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Income from Continuing Operations for 17 consecutive years, with 205991000.0 as the latest value for Q1 2026.

  • For Q1 2026, Income from Continuing Operations rose 1228.66% year-over-year to 205991000.0; the TTM value through Mar 2026 reached 543940000.0, up 336.01%, while the annual FY2025 figure was 313747000.0, 212.79% up from the prior year.
  • Income from Continuing Operations hit 205991000.0 in Q1 2026 for Alnylam Pharmaceuticals, up from 111543000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 292683000.0 in Q3 2025 and bottomed at 405920000.0 in Q3 2022.
  • Average Income from Continuing Operations over 5 years is 77874470.59, with a median of 83763000.0 recorded in 2024.
  • Year-over-year, Income from Continuing Operations plummeted 292.43% in 2025 and then skyrocketed 1228.66% in 2026.
  • Alnylam Pharmaceuticals' Income from Continuing Operations stood at 207493000.0 in 2022, then surged by 33.55% to 137870000.0 in 2023, then surged by 39.24% to 83763000.0 in 2024, then soared by 233.17% to 111543000.0 in 2025, then soared by 84.67% to 205991000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 205991000.0, 111543000.0, and 292683000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.